Canaccord analyst Edward Nash downgraded Oramed to Hold from Buy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ORMP:
- Oramed Crashes after Disappointing Topline Results
- Oramed’s results from phase 3 trial of ORMD-0801 did not meet primary endpoint
- Oramed granted combination therapy patent for treating diabetes
- Oramed’s ORMD-0801 meets primary endpoint in peer-reviewed publication
- Oramed Pharma Up After Positive Clinical Data